PT  - JOURNAL ARTICLE
AU  - Rahmat Azhari Kemal
AU  - Dita Kartika Sari
AU  - Ariza Julia Paulina
TI  - Antibody Response to CoronaVac Vaccine in Indonesian COVID-19 Survivor
AID  - 10.1101/2021.05.28.21254613
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.28.21254613
4099  - http://medrxiv.org/content/early/2021/05/29/2021.05.28.21254613.short
4100  - http://medrxiv.org/content/early/2021/05/29/2021.05.28.21254613.full
AB  - Several studies have shown that individuals with previous history of SARS-CoV-2 infection had boosted antibody response after single dose of mRNA or adenovirus-vectored vaccines. We wondered whether single dose CoronaVac, a whole-inactivated vaccine, could be considered for COVID-19 survivors in Indonesia. We measured IgG anti-RBD titre among 18 survivors and 37 non-survivors. Among survivors, there were 9 survivors with positive antibody titre (seropositive) before vaccination and 9 seronegative survivors. All respondents received two doses of CoronaVac vaccine at 14-days interval. We found no significant antibody titre difference between non-survivor at 14 or 28 days after second dose as well as seronegative survivor at at 14 days after second dose. Seropositive survivors were rapidly boosted after first dose with higher antibody titer than non-survivors and seronegative survivors after second dose. However, antibody titer did not differ between first and second dose among seropositive survivors. Seropositive COVID-19 survivors could receive single dose of CoronaVac vaccine which could potentially ease the vaccine supply constrain. A long-term follow-up must be conducted to observe difference in antibody response and persistence.Article Summary Line Seropositive COVID-19 survivors had significantly higher antibody response after first dose of CoronaVac vaccine compared to non-survivors and seronegative survivors after second dose of vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant from Faculty of Medicine, Universitas RiauAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol for the collection of blood samples from respondents was reviewed and approved by Ethical Committee of the Faculty of Medicine Universitas Riau (No: B/023/UN19.5.1.1.8/UEPPK/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes-